Cowen & Co. Keeps Their Buy Rating on Argenx Se (ARGX)

Cowen & Co. analyst Yaron Werber maintained a Buy rating on Argenx Se (ARGXResearch Report) yesterday. The company’s shares closed last Monday at $147.42, close to its 52-week high of $152.01.

According to TipRanks.com, Werber is a 5-star analyst with an average return of 19.5% and a 70.8% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Springworks Therapeutics, and Rocket Pharmaceuticals.

Currently, the analyst consensus on Argenx Se is a Strong Buy with an average price target of $159.00, which is a 6.7% upside from current levels. In a report issued on November 24, Stifel Nicolaus also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $152.01 and a one-year low of $88.05. Currently, Argenx Se has an average volume of 177.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia.